D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors

Purification of serine racemase: biosynthesis of the neuromodulator D-serine

High levels of D-serine occur in mammalian brain, where it appears to be an endogenous ligand of the glycine site of N-methyl-D-aspartate receptors. In glial cultures of rat cerebral cortex, D-serine is enriched in type II astrocytes and is released upon stimulation with agonists of non-N-methyl-D-aspartate glutamate receptors. The high levels of D-serine in discrete areas of rat brain imply the existence of a biosynthetic pathway. We have purified from rat brain a soluble enzyme that catalyzes the direct racemization of L-serine to D-serine. Purified serine racemase has a molecular mass of 37 kDa and requires pyridoxal 5'-phosphate for its activity. The enzyme is highly selective toward L-serine, failing to racemize any other amino acid tested. Properties such as pH optimum, Km values, and the requirement for pyridoxal phosphate resemble those of bacterial racemases, suggesting that the biosynthetic pathway for D-amino acids is conserved from bacteria to mammalian brain.

Modulation of NMDA receptors by glycine--introduction to some basic aspects and recent developments

Glycine is a co-agonist at NMDA receptors and it's presence is a prerequisite for channel activation by glutamate or NMDA. Physiological concentrations reduce one form of NMDA receptor-desensitization. Interactions between the glycineB site and other domains of the NMDA receptor are complex and include the glutamate, Mg2+ and polyamines sites. Glycine shows different affinities at various NMDA receptor subtypes probably via to allosteric interactions between NMDA2 subunits and the glycine recognition site on the NMDAR1 subunit. There is still some debate whether the glycineB site is saturated in vivo but it seems likely that this depends on regional differences in receptor subtype expression, local glycine or D-serine concentrations and the expression of specific glycine transporters. GlycineB antagonists and partial agonists have been reported to have good therapeutic indices as neuroprotective agents against focal ischaemia and trauma, anti-epileptics, anxiolytics, anti-psychotomimetics and in models of chronic pain. They clearly lack two potentially serious side effects classically associated with NMDA receptor blockade, namely neurodegenerative changes in the cingulate/retrosplenial cortex and psychotomimetic-like effects. This improved therapeutic profile may be partially due to the ability of full glycineB antagonists to reveal glycine-sensitive desensitization and possibly also via functional and/or regional NMDA receptor subtype selectivity.

Localization of the brain-specific high-affinity l-proline transporter in cultured hippocampal neurons: molecular heterogeneity of synaptic terminals

The expression of a brain-specific, high-affinity Na+-(and Cl--)dependent l-proline transporter in subpopulations of putative glutamatergic pathways in mammalian brain suggests a physiological role for this carrier in excitatory neurotransmission (Fremeau et al. , Neuron 8: 915-926, 1992). To assess further the cell-type and subcellular localization of PROT, we examined its distribution in low-density cultures of embryonic rat hippocampus. PROT immunoreactivity was detected beginning at 8 days in culture in a highly punctate pattern localizing to a subset of synaptic terminals. PROT was not detected at GABAergic terminals but was specifically localized to a subset of excitatory nerve terminals. PROT-labeled terminals showed partial apposition to AMPA-type and NMDA-type glutamate receptor clusters. Immunolabeling of isolated neurons grown in microisland cultures revealed that PROT was expressed by 60% of cultured hippocampal neurons. Individual microisland cultures were immunopositive for either PROT or glutamic acid decarboxylase, but never both. In the expressing pyramidal neurons, PROT was targeted to all presynaptic terminals. These findings indicate that PROT contributes to the molecular heterogeneity of glutamatergic terminals and suggest a novel presynaptic regulatory role for PROT in excitatory transmission at specific glutamatergic synapses.

D-serine added to antipsychotics for the treatment of schizophrenia

BACKGROUND

Hypofunction of N-methyl-D-aspartate (NMDA) subtype glutamate receptor has been implicated in the pathophysiology of schizophrenia. D-serine is a full agonist of the glycine site of NMDA receptor, an endogenous cotransmitter enriched in corticolimbic regions and distributed in parallel with NMDA receptor. Supplementation of D-serine may improve the symptoms of schizophrenia.

METHODS

Thirty-one Taiwanese schizophrenic patients enrolled in a 6-week double-blind, placebo-controlled trial of D-serine (30 mg/kg/day), which was added to their stable antipsychotic regimens. Of these, 28 completed the trial. Measures of clinical efficacy, side effects, and serum levels of amino acids and D-serine were determined every other week. Wisconsin Card Sorting Test (WCST) was performed at the beginning and end of the trial.

RESULTS

Patients who received D-serine treatment revealed significant improvements in their positive, negative, and cognitive symptoms as well as some performance in WCST. D-serine levels at week 4 and 6 significantly predicted the improvements. D-serine was well tolerated and no significant side effects were noted.

CONCLUSIONS

The significant improvement with the D-serine further supports the hypothesis of NMDA receptor hypofunction in schizophrenia. Given the effects of D-serine on positive symptoms, a trial of D-serine alone in schizophrenia should be considered.

Attenuated neurotransmitter release and spreading depression-like depolarizations after focal ischemia in mutant mice with disrupted type I nitric oxide synthase gene

Nitric oxide (NO) plays a complex role in the pathophysiology of cerebral ischemia. In this study, mutant mice with disrupted type I (neuronal) NO synthase (nNOS) were compared with wild-type littermates after permanent focal ischemia. Cerebral blood flow in the central and peripheral zones of the ischemic distribution were measured with laser doppler flowmetry. Simultaneously, microdialysis electrodes were used to measure extracellular amino acid concentrations and DC potential in these same locations. Blood flow was reduced to <25 and 60% of baseline levels in the central and peripheral zones, respectively; there were no differences in nNOS mutants versus wild-type mice. Within the central ischemic zone, DC potentials rapidly shifted to -20 mV in all mice. In the ischemic periphery, spreading depression (SD)-like waves of depolarization were observed. SD-like events were significantly fewer in the nNOS mutant mice. Concurrent with these hemodynamic and electrophysiological perturbations, extracellular elevations in amino acids occurred after ischemia. There were no detectable differences between wild-type and mutant mice in the ischemic periphery. However, in the central zone of ischemia, elevations in glutamate and GABA were significantly lower in the nNOS mutants. Twenty-four hour infarct volumes in the nNOS mutant mice were significantly smaller than in their wild-type littermates. Overall, the number of SD-like depolarizations and the integrated efflux of glutamate were significantly correlated with infarct size. These results suggest that NO derived from the nNOS isoform contributes to tissue damage after focal ischemia by amplifying excitotoxic amino acid release in the core and deleterious waves of SD-like depolarizations in the periphery.

Emergence of D-aspartic acid in the differentiating neurons of the rat central nervous system

The rat embryonic brain was probed with anti-d-aspartic acid (d-Asp) antiserum at different stages of development. At gestational day (E) 12, weak immunoreactivity (IR) of d-Asp was apparent at the hindbrain, midbrain and caudal forebrain, whereas it became more intense and extended over the whole brain at E20. However, IR markedly decreased after parturition. In the region of the immature forebrain at an early stage of development (E12), IR was mainly a characteristic of the cytoplasm of the neuronal cells, while in the more mature hindbrain it was localized in the axonal zone. In the more differentiated forebrain at a later stage of development (E18), the IR became restricted to zones which mainly consisted of axons and processes. Consequently, in the rat central nervous system, d-Asp first emerges during embryonic development as a feature of the cytoplasm and thereafter spreads into the axonal regions of neuronal cells, before disappearing almost completely after parturition.

Occurrence of pyridoxal 5'-phosphate-dependent serine racemase in silkworm, Bombyx mori

D-Serine is known to occur in the silkworm Bombyx mori as well as in the mammalian central nervous systems. We found that serine racemase occurs in the insect, catalyzing the conversion of L-serine to its antipode. The enzyme was partially purified from pupae of the insect, and was inactivated by treatment with hydroxylamine and reactivated with pyridoxal 5'-phosphate (PLP). L-Alanine was racemized slowly by the enzyme at a rate of only about 6% of that of L-serine, and L-arginine and L-glutamine were inert as substrates. Therefore, the enzyme is a member of PLP-dependent amino acid racemases, and is distinct from alanine racemase (EC 5.1.1.1) and amino acid racemase with low substrate specificity (EC 5.1.1.10). This is the first report of the occurrence of serine racemase in eukaryotes producing D-serine.

The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis

The effect of the N-methyl-D-aspartate (NMDA) receptor antagonist (5R, 10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-5,10-i mine hydrogen maleate (MK-801) was examined on c-fos-like immunoreactivity (c-fos-LI) in urethane-anesthetized Sprague-Dawley rats using a polyclonal antibody. C-fos, an indicator of neuronal activation, was assessed within the trigeminal nucleus caudalis (TNC), area postrema. lateral reticular and solitary tract nuclei 2 h after intracisternal injection of capsaicin. C-fos-positive cells were counted at three representative levels corresponding to obex, -2.05 mm and -6.45 mm in 18 tissue sections (50 microm). A weighted average was obtained reflecting total brainstem expression within lamina I, II of TNC using a recently validated method. Capsaicin (0.1, 1, 5, 10 and 15 nmol) caused a dose-dependent labeling of cells in lamina I, II at obex similar to that previously reported after intracisternal blood or carrageenin administration in rats and guinea pigs. MK-801 (0.3, 1 and 3 mg/kg) administered i.p. 30 min before capsaicin (5 nmol in 100 microl artificial CSF) reduced significantly and dose-dependently (12%, 36% and 47%, respectively) the c-fos-LI cells in TNC at each level from rostral to caudal but not in solitary tract, area postrema and lateral reticular nuclei, and for unexplained reasons, increased c-fos-LI within the inferior olive. These results suggest that NMDA receptors provide a potential therapeutic target for cephalic pain (e.g. migraine) due to trigeminovascular activation from meningeal afferents.

Alterations in K+ evoked profiles of neurotransmitter and neuromodulator amino acids after focal ischemia-reperfusion

Secondary elevations in extracellular amino acids occur during reperfusion after transient cerebral ischemia. The delayed accumulation of excitatory amino acids may contribute to the progressive development of neuronal injury. In this study, we explored the mechanisms that may be involved in this phenomenon. Microdialysis samples from probes located in rabbit cortex were analysed with a chiral amino acid procedure. Concentrations of neurotransmitters (L-Glu, GABA), N-methyl-D-aspartate receptor modulators (D-Ser, Gly), an inhibitory neuromodulator (Tau), the lipid component phosphoethanolamine, and L-Gln, L-Ser and L-Ala were measured. Depolarization via perfusion with potassium was used to assess the status of release/reuptake systems at 2 and 4 h reperfusion after 2 h transient focal ischemia. Background experiments classified potassium evoked responses as calcium dependent or calcium-independent by inclusion of 30 microM omega-conopeptide MVIIC or by inclusion of 20 mM magnesium and ommision of calcium. During ischemia, large elevations of almost all amino acids occurred. During reperfusion, secondary elevations in transmitter amino acids (L-Glu, GABA) and N-methyl-D-aspartate receptor modulators (D-Ser, Gly) occurred. Tau remained slightly elevated whereas the lipid component phosphoethanolamine remained high and stable during reperfusion. Reperfusion significantly potentiated the potassium response for amino acids with calcium-dependent responses (L-Glu and GABA). In contrast, calcium-independent responses (Tau, phosphoethanolamine, L-Gln) were significantly attenuated. Intermediate behavior was observed with Gly, while no potassium responses were observed for D-Ser, L-Ser or L-Ala. These data demonstrate that perturbations in evoked amino acid profiles after ischemia-reperfusion are selective. Reduction of calcium-independent responses implicate a general decline in efficacy of transporter mechanisms that restore transmembrane gradients of ions and transmitters. Decreased efficacy of transporter systems may reduce transmitter reuptake and account for the amplified release of L-Glu and GABA, thus contributing to progressive neural dysfunction after cerebral ischemia.

Nonsynaptic glycine receptor activation during early neocortical development

Glycine receptors (GlyRs) contribute to fast inhibitory synaptic transmission in the brain stem and spinal cord. GlyR subunits are expressed in the developing neocortex, but a neurotransmitter system involving cortical GlyRs has yet to be demonstrated. Here, we show that GlyRs in immature neocortex are excitatory and activated by a nonsynaptically released endogenous ligand. Of the potential ligands for cortical GlyRs, taurine is by far the most abundant in the developing neocortex. We found that taurine is stored in immature cortical neurons and that manipulations known to elevate extracellular taurine cause GlyR activation. These data indicate that nonsynaptically released taurine activates GlyRs during neocortical development. As fetal taurine deprivation can cause cortical dysgenesis, it is possible that taurine influences neocortical development by activating GlyRs.

The rat dermorphin-like immunoreactivity is supported by an aminopeptidase resistant peptide

Site-directed antibodies against synthetic related dermorphin peptides were previously produced and characterized. One of them, which specifically recognizes the crucial 'opioid message' (the N-terminal part of the dermorphin molecule (i.e. Tyr-D-Ala-Phe-Gly) was selected in order to detect and locate endogenous dermorphin-like molecules in rat, mouse and guinea pig tissues. Dermorphin-like peptides were found to be present in tissues known to contain peptides such as neurons in the central nervous system, nerve fibers in the gut and B and T immune cells. With all the tissues assayed, the HPLC profile obtained on the immunoreactive material showed the same main peak eluted at a retention time of 32 +/- 1 min. The results of biochemical experiments in which enzymatic treatments were performed on the dermorphin-like immunoreactivity indicate the immunoreactivity is a peptide resistant to aminopeptidase hydrolysis. This finding suggests the presence of a residue conferring resistance to proteolytic processes of this kind, which is likely to be a D-amino acid residue.

Uptake of D- and L-serine in C6 glioma cells

Cultured C6 glioma cells were able to accumulate [3H]D- and [3H]L-serine in a temperature- and Na+-dependent and saturable manner. The kinetic analysis of these accumulation phenomena indicates that the D- or L-serine uptake into the glioma cells might occur by a single-component system with an apparent Km value around 2480 microM (for D-serine) or 110 microM (for L-serine) and a Vmax value around 7 nmol/min per mg protein. The ratio of the L- to D-serine uptake affinity was similar to that previously reported in the astrocytes of rat cerebrum. The inhibition profiles of D- and L-serine uptake by various amino acid and related compounds resembled each other and those of the ASCT-like neutral amino acid transporter. The present findings therefore suggest that C6 glioma cells may accumulate D- and L-serine through a common ASCT-like transporter and provide a useful model for the glial uptake of extracellular D- and L-serine in the brain.

Novel phosphoserine phosphatase inhibitors

Phosphoserine phosphatase (EC 3.1.1.3) catalyzes the final step in the major pathway of L-serine biosynthesis in brain. This enzyme may also regulate the levels of glycine and D-serine, the known and putative co-agonists for the glycine site of the N-methyl-D-aspartate receptor in caudal and rostral brain regions, respectively. Using L-phosphoserine as substrate, the rank order potency for inhibition of phosphoserine phosphatase was p-chloromercuriphenylsulfonic acid (CMPSA) > glycerophosphorylcholine >> hexadecylphosphocholine > or = phosphorylcholine > N-ethylmaleimide > or = L-serine > fluoride > D-2-amino-3-phosphonopropionic acid (D-AP3). Glycerylphosphorylcholine (IC50 18 microM) was found to be an uncompetitive inhibitor of phosphoserine phosphatase. Glycerylphosphorylcholine probably binds a novel site on the enzyme since the known allosteric inhibitor L-serine is highly selective for its feedback regulatory site, indicated by the inactivity of 25 L-serine analogs. Fluoride ion (IC50 770 microM) may bind the active site as has been shown for other Mg2+-dependent enzymes. The sulfhydryl reagent CMPSA is a potent, noncompetitive inhibitor of the enzyme using L-phosphoserine as substrate (IC50 9 microM) but is > 300-fold less potent using D-phosphoserine as substrate. Substrate-dependent differences are also observed with the sulfhydryl alkylator N-ethylmaleimide, which inhibits L-phosphoserine, but stimulates D-phosphoserine hydrolysis. These sulfhydryl reagents may dissociate multimeric forms of the enzyme to form monomers; the multimeric forms and monomers may preferentially cleave L- and D-phosphoserine, respectively. Phosphorylcholine esters and sulfhydryl reagents may prove useful in determining the contribution of phosphoserine phosphatase to the biosynthesis of glycine and D-serine in neuronal tissue in vitro.

Distribution of D-amino acid oxidase (DAO) activity in the medulla and thoracic spinal cord of the rat: implications for a role for D-serine in autonomic function

The activity and regional distribution of D-amino acid oxidase (DAO), an enzyme that inactivates D-serine, were examined in the medulla and spinal cord of the rat by biochemical and histochemical procedures. DAO activity was noticeably low or absent in the nucleus of the solitary tract, ventrolateral medulla and intramediolateral cell column of the spinal cord. This may be indicative of a neuromodulatory role for endogenous D-serine (at the NMDA-glycine site) in in the central control of blood pressure.

Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes

We present evidence that membrane transporters can control the membrane receptor's agonist concentration in restricted extracellular spaces of a biological model. The model is constructed by co-expressing glycine/Na/Cl cotransporters (GLYT1b) and NMDA receptors (NMDARs) (composed of the subunits NR1 and NR2A or NR2B) in Xenopus oocytes. We use the high-affinity glycine site of the NMDARs as a sensor of the actual juxtamembrane glycine concentration. We show that glycine uptake by GLYT1b dramatically reduces NMDAR currents by reducing the glycine concentration in extracellular spaces in which diffusion is restricted. This effect appears only in oocytes in which GLYT1b and NMDAR are co-expressed. It is Na+- and voltage-dependent, and is abolished when Na+ is replaced by Li+ and when glycine is replaced by D-serine (a coagonist of the NMDAR that is not transported by GLYT1b). These results demonstrate the ability of the GLYT transporter to reduce glycine concentration at the level of NMDARs in restricted diffusion spaces. This observation could account for a prevalent role of membrane transporters in the modulation of synapse transmission in the CNS. From a more general point of view, our results draw attention to possible significant discrepancies between local concentrations at the level of substrate targets in biological membranes and their concentration in the bulk solution when membrane transporters are present.

The origin and turnover of D-serine in brain

The origin of D-serine was investigated using microdialysis probes to administer radiolabeled glucose, glycine, and L-serine directly into rat brain. In these experiments the labeling of D-serine was found to be determined only by the radioactivity present in the L-serine pool, regardless of the precursor employed, indicating that L-serine is the direct precursor of the D-isomer. Its rate of synthesis was 4.6 +/- 1.2 %/h; 9.2 nmol/g/h). This rate of synthesis is in agreement with that found in the mouse after a loading dose of intraperitoneally injected L-[3H]-serine (4.1 %/h). These rates are also consistent with the degradation rates of D-serine in rat and mouse brain, determined in pulse labeling experiments (4.1 and 3.8 %/h, respectively). Synthesis within the brain from L-serine therefore is adequate to account for the turnover of the brain D-serine pool: contributions from other sources, including the diet, must be minimal. Independence from dietary sources was also demonstrated by the failure of labeled D-serine administered in the drinking water to label the brain pool unless very high doses were given. These results suggest that D-serine in the brain is formed directly by the racemization of L-serine.